BR112013004766A2 - 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3 - Google Patents
2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3Info
- Publication number
- BR112013004766A2 BR112013004766A2 BR112013004766A BR112013004766A BR112013004766A2 BR 112013004766 A2 BR112013004766 A2 BR 112013004766A2 BR 112013004766 A BR112013004766 A BR 112013004766A BR 112013004766 A BR112013004766 A BR 112013004766A BR 112013004766 A2 BR112013004766 A2 BR 112013004766A2
- Authority
- BR
- Brazil
- Prior art keywords
- carboxamides
- quinoline
- amino
- substituted
- kcnq2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3. a presente invenção refere-se às 2-amino-quinolina-3-carboxamidas substituídas, às composições farmacêuticas contendo estes compostos e também a estes compostos para uso no tratamento e/ou profilaxia de dor e outras doenças e/ou distúrbios.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10008922 | 2010-08-27 | ||
PCT/EP2011/004278 WO2012025237A1 (en) | 2010-08-27 | 2011-08-26 | Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013004766A2 true BR112013004766A2 (pt) | 2016-08-02 |
Family
ID=43243680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013004766A BR112013004766A2 (pt) | 2010-08-27 | 2011-08-26 | 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8470852B2 (pt) |
EP (1) | EP2609084A1 (pt) |
JP (1) | JP5887345B2 (pt) |
AR (1) | AR082733A1 (pt) |
AU (1) | AU2011295406B2 (pt) |
BR (1) | BR112013004766A2 (pt) |
CA (1) | CA2805932A1 (pt) |
MX (1) | MX2013000748A (pt) |
TW (1) | TW201211007A (pt) |
WO (1) | WO2012025237A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
RU2595894C2 (ru) * | 2010-08-27 | 2016-08-27 | Грюненталь Гмбх | Замещенные 2-окси-хинолин-3-карбоксамиды в качестве модуляторов kcnq2/3 |
AR082813A1 (es) | 2010-09-01 | 2013-01-09 | Gruenenthal Gmbh | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3 |
AU2013329832A1 (en) * | 2012-10-11 | 2015-05-28 | Grunenthal Gmbh | Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders |
CA2892652A1 (en) | 2012-11-28 | 2014-06-05 | Grunenthal Gmbh | Heteroquinoline-3-carboxamides as kcnq2/3 modulators |
US9248122B2 (en) | 2012-11-28 | 2016-02-02 | Grünenthal GmbH | Heteroquinoline-3-carboxamides as KCNQ2/3 modulators |
JP2016508960A (ja) | 2012-11-28 | 2016-03-24 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Kcnq2/3モジュレーターとしての特定のカルボキサミド |
WO2014127214A1 (en) | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
CA2900680C (en) | 2013-02-20 | 2021-08-10 | Kala Pharmaceuticals, Inc. | Quinoline and quinazoline compounds and uses thereof for treating and/or preventing diseases |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
MX355330B (es) | 2013-11-01 | 2018-04-16 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapeuticos y sus usos. |
WO2018048747A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10336767B2 (en) | 2016-09-08 | 2019-07-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
GEP20247590B (en) | 2019-12-27 | 2024-02-12 | Tecnimede Soc Tecnico Medicinal Sa | Antibacterial quinolines |
CA3223626A1 (en) | 2021-06-29 | 2023-01-05 | Augusto Eugenio Pardal Filipe | Heterocyclic compounds for the treatment of tuberculosis |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2706977A1 (de) | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
FR2482596A1 (fr) | 1980-05-19 | 1981-11-20 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament |
DE3111934A1 (de) | 1981-03-26 | 1982-10-07 | Bayer Ag, 5090 Leverkusen | Oel-in-wasser-emulsionen, verfahren zu deren herstellung und deren verwendung |
FR2509728A1 (fr) | 1981-07-17 | 1983-01-21 | Roussel Uclaf | Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
DE3210063A1 (de) | 1982-03-19 | 1983-09-22 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
DE3211934A1 (de) | 1982-03-31 | 1983-10-13 | Hoechst Ag, 6230 Frankfurt | Salicylsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
FR2532939A1 (fr) * | 1982-09-13 | 1984-03-16 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus |
DE4032147A1 (de) | 1990-10-10 | 1992-04-16 | Bayer Ag | Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung |
US5525611A (en) | 1993-06-04 | 1996-06-11 | Behforouz; Mohammad | Lavendamycin analogs and methods of making and using them |
US6030983A (en) | 1993-06-04 | 2000-02-29 | Ball State University | Lavendamycin analogs, quinoline-5,8-diones and methods of using them |
ATE188377T1 (de) | 1993-06-29 | 2000-01-15 | Takeda Chemical Industries Ltd | Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose |
EP0716077A1 (de) | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
WO1996026925A1 (fr) | 1995-03-01 | 1996-09-06 | Banyu Pharmaceutical Co., Ltd. | Derives de l'arylthioacetamide |
DE19738616A1 (de) | 1997-09-04 | 1999-03-11 | Clariant Gmbh | 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel |
GB9807114D0 (en) | 1998-04-02 | 1998-06-03 | Smithkline Beecham Plc | Novel process |
JP2000256323A (ja) | 1999-01-08 | 2000-09-19 | Japan Tobacco Inc | 2−オキソキノリン化合物及びその医薬用途 |
WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
CA2378243C (en) | 1999-08-04 | 2012-05-15 | Icagen, Inc. | Methods for treating or preventing pain and anxiety |
JP2003506387A (ja) | 1999-08-04 | 2003-02-18 | アイカゲン インコーポレイテッド | カリウムチャンネルオープナーとしてのベンズアニリド |
RS51019B (sr) | 1999-10-25 | 2010-10-31 | Active Biotech Ab. | Lekovi za lečenje malignih tumora |
JP2005507853A (ja) | 2001-02-20 | 2005-03-24 | ブリストル−マイヤーズ スクイブ カンパニー | Kcnqカリウムチャンネルモジュレーター並びに片頭痛および機構的に関連する疾患の治療におけるそれらの使用 |
MXPA03007395A (es) | 2001-02-20 | 2003-12-04 | Bristol Myers Squibb Co | Derivados de pirimidin-5-carboxamida 2,4-disustituida como moduladores del canal de potasio kcnq. |
US6593349B2 (en) | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
AU2002256085A1 (en) | 2001-04-06 | 2002-10-21 | Smithkline Beecham Corporation | Quinoline inhibitors of hyak1 and hyak3 kinases |
BR0314390A (pt) | 2002-09-17 | 2005-07-19 | Pharmacia Corp | Moduladores aromáticos dos receptores hepáticos x |
CA2498046A1 (en) | 2002-09-18 | 2004-04-01 | The Curators Of The University Of Missouri | Opiate analogs selective for the delta-opioid receptor |
DE60335028D1 (de) | 2002-12-23 | 2010-12-30 | Icagen Inc | Quinazolinone als kaliumkanalmodulatoren |
EP1449841A1 (en) | 2003-02-19 | 2004-08-25 | Bayer CropScience SA | New fungicidal compounds |
WO2004080463A1 (en) * | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
EP1604983A4 (en) | 2003-03-17 | 2008-06-25 | Takeda Pharmaceutical | Receptor Antagonists |
RU2006115602A (ru) | 2003-10-08 | 2007-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы переносчиков атф-связывающих кассет |
WO2005049608A1 (en) | 2003-11-24 | 2005-06-02 | Pfizer Japan, Inc. | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity |
AR048669A1 (es) | 2004-03-03 | 2006-05-17 | Syngenta Ltd | Derivados biciclicos de bisamida |
AP2006003769A0 (en) | 2004-05-04 | 2006-10-31 | Pfizer | Ortho substituted aryl or heteroaryl amide compounds |
EP1814856A1 (en) | 2004-11-12 | 2007-08-08 | Galapagos N.V. | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
PL2298766T3 (pl) | 2005-03-03 | 2014-09-30 | H Lundbeck As | Preparaty farmaceutyczne zawierające podstawione pochodne pirydyny |
DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
US8133907B2 (en) | 2005-07-20 | 2012-03-13 | Eli Lilly And Company | Pyridine derivatives as dipeptedyl peptidase inhibitors |
EP1922311A2 (en) | 2005-09-09 | 2008-05-21 | Brystol-Myers Squibb Company | Acyclic ikur inhibitors |
JP2009515934A (ja) | 2005-11-18 | 2009-04-16 | ノイロサーチ アクティーゼルスカブ | 新規なキナゾリン誘導体及びこれらの医学的使用 |
US7728130B2 (en) | 2005-12-09 | 2010-06-01 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity |
US7763607B2 (en) | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
US20120088746A1 (en) | 2006-05-10 | 2012-04-12 | Pfizer Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
US8134004B2 (en) | 2006-07-11 | 2012-03-13 | Pfizer Inc. | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds |
AU2007275683B2 (en) | 2006-07-20 | 2012-05-10 | Amgen Inc. | Di-amino-substituted heterocyclic compounds and methods of use |
WO2008011080A2 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Benzo(d) isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine |
WO2008014307A2 (en) | 2006-07-26 | 2008-01-31 | Novartis Ag | Inhibitors of undecaprenyl pyrophosphate synthase |
US20100022589A1 (en) | 2006-07-27 | 2010-01-28 | Mccoull William | Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
US20100069380A1 (en) | 2006-09-22 | 2010-03-18 | Soongyu Choi | Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof |
DE102006049452A1 (de) | 2006-10-17 | 2008-05-08 | Grünenthal GmbH | Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln |
JP2010512305A (ja) * | 2006-10-23 | 2010-04-22 | ファイザー株式会社 | 置換フェニルメチルビシクロカルボキシアミド化合物 |
WO2008097976A1 (en) | 2007-02-09 | 2008-08-14 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
US9162984B2 (en) | 2007-03-30 | 2015-10-20 | University Of Rochester | Small-molecule modulators of melanin expression |
US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
KR101167773B1 (ko) | 2007-08-03 | 2012-07-24 | 에프. 호프만-라 로슈 아게 | Taar1 리간드로서의 피리딘카복스아마이드 및 벤즈아마이드 유도체 |
EP2215065B1 (en) | 2007-10-19 | 2012-07-11 | Boehringer Ingelheim International GmbH | Ccr10 antagonists |
US8119656B2 (en) | 2007-12-07 | 2012-02-21 | The Board Of Regents Of The University Of Texas System | Inhibitors of the influenza virus non-structural 1 protein |
US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
US8513295B2 (en) | 2008-09-23 | 2013-08-20 | Georgetown University | Viral and fungal inhibitors |
MX2011003849A (es) | 2008-10-24 | 2011-05-23 | Gruenenthal Gmbh | 4,5,6,7-tetrahidrotienopiridinas sustituidas como moduladores de kcnq2/3. |
US20100125091A1 (en) * | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds as ion channel modulators |
US8367700B2 (en) | 2008-12-17 | 2013-02-05 | Gruenenthal Gmbh | Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators |
WO2010094644A1 (en) * | 2009-02-17 | 2010-08-26 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
WO2010094645A1 (en) | 2009-02-17 | 2010-08-26 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
TWI504395B (zh) | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
MX2011008825A (es) | 2009-03-10 | 2011-09-21 | Gruenenthal Gmbh | 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3. |
TW201038565A (en) | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier |
-
2011
- 2011-08-26 JP JP2013525187A patent/JP5887345B2/ja not_active Expired - Fee Related
- 2011-08-26 AR ARP110103118A patent/AR082733A1/es unknown
- 2011-08-26 US US13/218,536 patent/US8470852B2/en not_active Expired - Fee Related
- 2011-08-26 MX MX2013000748A patent/MX2013000748A/es active IP Right Grant
- 2011-08-26 TW TW100130609A patent/TW201211007A/zh unknown
- 2011-08-26 AU AU2011295406A patent/AU2011295406B2/en not_active Ceased
- 2011-08-26 WO PCT/EP2011/004278 patent/WO2012025237A1/en active Application Filing
- 2011-08-26 EP EP11754834.7A patent/EP2609084A1/en not_active Withdrawn
- 2011-08-26 BR BR112013004766A patent/BR112013004766A2/pt not_active IP Right Cessation
- 2011-08-26 CA CA2805932A patent/CA2805932A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR082733A1 (es) | 2012-12-26 |
US8470852B2 (en) | 2013-06-25 |
AU2011295406B2 (en) | 2015-08-06 |
WO2012025237A1 (en) | 2012-03-01 |
US20120220627A1 (en) | 2012-08-30 |
JP2013536211A (ja) | 2013-09-19 |
CA2805932A1 (en) | 2012-03-01 |
TW201211007A (en) | 2012-03-16 |
MX2013000748A (es) | 2013-03-05 |
JP5887345B2 (ja) | 2016-03-16 |
WO2012025237A9 (en) | 2013-02-14 |
AU2011295406A1 (en) | 2013-01-17 |
EP2609084A1 (en) | 2013-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013004766A2 (pt) | 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3 | |
EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
BR112014020826A2 (pt) | moduladores e métodos de uso | |
BR112015010663A2 (pt) | formas de dosagem de ruxolitinib de liberação sustentada | |
BR112015019720B8 (pt) | Inibidores de (benzil-ciano-metil)-amidas de ácido 2-azabiciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c e composição farmacêutica | |
BR112013004562A2 (pt) | 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3 | |
AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
IN2013CN01340A (pt) | ||
AU2012253759A8 (en) | Tricyclic sulfonamide compounds and methods of making and using same | |
BR112013004721A2 (pt) | "quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3" | |
ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
CL2012001605A1 (es) | Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño. | |
GT201200258A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
BR112014001908A2 (pt) | derivados aza heterocíclicos substituídos | |
MX2014008706A (es) | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. | |
UA113538C2 (xx) | Фторметил-5,6-дигідро-4h-$1,3]оксазини | |
BR112015004306A2 (pt) | fluorometil-substituído pirrol carboxamidas | |
EA201492097A1 (ru) | 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1 | |
WO2014035846A3 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | |
CY1116158T1 (el) | Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. | |
BR112014001714A2 (pt) | derivados de carboxamida e ureia aromáticos bicíclicos substituídos como ligantes de receptor vaniloide | |
BR112013005056A2 (pt) | 1-oxo-di-hidroisoquinolina-3-carboxamidas substituídas como moduladores kcnq2/3 | |
BR112014006675A2 (pt) | derivados de metanossulfonamida substituídos como ligantes de receptor vaniloide | |
MX2016007955A (es) | Pirrol carboxamidas iii fluorometil-sustituidas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2476 DE 19-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |